Clinical trials: Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Chronic Kidney Disease, Heart Failure With Reduced Ejection Fraction (HFrEF)
Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure
This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT07259512
- Testing
- Ramipril
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Evi Liliek Wulandari
HFrEF - Heart Failure With Reduced Ejection Fraction, Chronic Kidney Disease
Swedish Cardiac And Renal Failure Study-1
Previous studies have shown that patients with heart failure with reduced pumping function and preserved kidney function experience improved symptoms, longer survival, and fewer hospitalizations when treated with medications such…
- Trial name
- SCARF-1 (NCT07029503)
- Testing
- Eplerenone
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska Institutet
Chronic Heart Failure
Cost and Shared Decision-Making for Heart Failure
This study is designed to understand the impact of providing patient-specific cost at the time of the clinical encounter on decision-making for heart failure medications.
- Trial name
- NCT04793880
- Testing
- Medication Cost Information, Heart Failure Medicines Checklist
- Where
- 4 sites in United States
- Volunteers
- 247 people
- Sponsor
- Emory University
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study, Called VERI-China, to Learn More About How Well Vericiguat Works and How Safe it is in Real-world Setting in People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in China
This is an observational study in which data from people in China with chronic heart failure with reduced ejection fraction (HFrEF) who will be receiving vericiguat treatment are collected.
- Trial name
- VERI-China (NCT05728502)
- Testing
- Vericiguat (Verquvo, BAY1021189), Standard of Care (SoC)
- Where
- China
- Volunteers
- 2,400 people
- Sponsor
- Bayer
Chronic Total Occlusion Vessel
Benefits of CTO-PCI in Selected Cases With HFrEF (CTOHFrEF)
The investigators studied the effect of CTO-PCI on left ventricular function and clinical parameters in patients with HFrEF.
- Trial name
- CTOHFrEF (NCT02570087)
- Testing
- chronic total coronary occlusion percutaneous intervention
- Volunteers
- 39 people
- Sponsor
- Hospital Clinic of Barcelona
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Beta 3 Agonist Treatment in Heart Failure
Objective: The objective of the study is to assess the structural and functional cardiac effects of treatment with the beta 3 AR agonist Mirabegron in patients with chronic heart failure.
- Trial name
- Beat-HF (NCT01876433)
- Testing
- Mirabegron
- Where
- 3 sites in Australia, Denmark
- Volunteers
- 70 people
- Sponsor
- Henning Bundgaard
Chronic Heart Failure, Cardiovascular Diseases
AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices
The goal of this observational, multicenter study is to evaluate whether AI-driven remote monitoring using a mini-invasive wearable device can improve clinical outcomes in adult patients (≥18 years) with chronic heart failure…
- Conditions
- Chronic Heart Failure, Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure With Preserved Ejection Fraction (HFPEF)
- Trial name
- SMART-CARE (NCT06909682)
- Testing
- Intervention Group (Device Group - AI-Based Remote Monitoring), Standard Clinical Follow-Up
- Where
- Italy
- Volunteers
- 205 people
- Sponsor
- University of Salerno
Heart Failure With Reduced Ejection Fraction, Heart Failure
Effects of a Single Oral Dose of KETone Ester ON Exercise Performance in Patients With Chronic Heart Failure
In a randomized, double-blind, placebo-controlled cross-over design, subjects will either receive a supplemental drink containing a commercially available ketone ester (DeltaG®, 500 mg/kg body weight), or a taste matched…
- Trial name
- KETONE-HF (NCT05348460)
- Testing
- Ketone ester drink (DeltaG®, 500 mg/kg body weight)
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen
Heart Failure
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
- Trial name
- NATRIX-BNP (NCT06237309)
- Testing
- REGN5381
- Where
- 44 sites in United States, Belgium and 10 more
- Volunteers
- 89 people
- Sponsor
- Regeneron Pharmaceuticals
Type 2 Diabetes, Heart Failure, Reduced Ejection Fraction
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT06108076
- Testing
- Ketone Monoester (KE)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Chronic Heart Failure With Reduced Ejection Fraction, Worsening Chronic Heart Failure
An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions
This is an observational study in which data already collected from people with chronic HFrEF (heart failure with reduced ejection fraction) who have experienced worsening heart failure are studied.
- Trial name
- NCT06632483
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- India
- Volunteers
- 604 people
- Sponsor
- Bayer
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced…
- Trial name
- NCT01951625
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 157 sites in United States, Australia and 22 more
- Volunteers
- 456 people
- Sponsor
- Bayer
Heart Failure
Effect of Pre-Hospital ARNI Therapy on Short-Term Outcomes in HFrEF
This study looks at people with heart failure who are admitted to the hospital. The goal of the study is to understand whether taking a heart failure medicine called angiotensin receptor-neprilysin inhibitor (ARNI) before…
- Trial name
- NCT07347925
- Testing
- Prehospital ARNI use, No prehospital ARNI use
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Future University in Egypt
Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
This study will evaluate the V-Wave Ventura Interatrial shunt. The Shunt is a small, hourglass-shaped device implanted in the dividing wall (septum) between the right and left atria (top chambers) of the heart placed during a…
- Conditions
- Heart Failure and Reduced Ejection Fraction, Heart Failure Chronic, Heart Failure New York Heart Association Class III, Heart Failure Congestive
- Trial name
- RELIEVE-HFrEF (NCT07696975)
- Testing
- Implantation of the V-Wave Interatrial shunt
- Volunteers
- 250 people
- Sponsor
- V-Wave Ltd
Cardiomyopathy, Dilated, Heart Failure
The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor
Chronic heart failure (CHF) is one of the major causes of death in Western societies. Evidence has accumulated that functionally active autoantibodies directed against the beta1 adrenergic receptor (β1 AAb) are of…
- Conditions
- Cardiomyopathy, Dilated, Heart Failure, Autoantibodies
- Trial name
- NCT04192214
- Testing
- BC 007
- Where
- 3 sites in Serbia
- Volunteers
- 30 people
- Sponsor
- Berlin Cures GmbH
Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Telemonitoring of HFrEF Patients
The aim of this study is to find out whether remote health monitoring can help people with chronic heart failure. For 3 months, some patients use a SiDLY CARE PRO electronic wristband.
- Trial name
- NCT07835490
- Testing
- Telemonitoring wristband
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Medical University of Lodz
Heart Failure With Reduced Ejection Fraction (HFrEF)
Telemedicine-guided Uptitration of Therapy in Chronic Heart Failure
This is a single-center, randomized, open-label, no-profit interventional trial designed to evaluate the effectiveness of a telemedicine-based follow-up strategy compared with standard ambulatory care in patients with newly…
- Trial name
- TELEHEART (NCT07518030)
- Testing
- Telemedicine-based follow-up, Standard follow-up
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Azienda Unita Sanitaria Locale di Piacenza
Chronic Heart Failure With Reduced Ejection Fraction
The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction
This is an observational study in which the health data of people with chronic heart failure with reduced ejection fraction (HFrEF) are collected using administrative claims data.
- Trial name
- NCT05974189
- Where
- Germany
- Volunteers
- 1,391 people
- Sponsor
- Bayer
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction. Chronic heart failure with reduced ejection fraction (HFrEF) is a long-term condition that occurs when the…
- Trial name
- NCT06195930
- Testing
- Vericiguat (BAY1021189) 5 mg
- Where
- 35 sites in United States, Argentina and 5 more
- Volunteers
- 106 people
- Sponsor
- Bayer
Chronic Heart Failure With Reduced Ejection Fraction
Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
The purpose of the study was to determine the effect of LCZ696 vs. enalapril on improvement of exercise capacity in patients with chronic heart failure with reduced ejection fraction.
- Trial name
- NCT02768298
- Testing
- LCZ696, Enalapril
- Where
- 34 sites in Germany
- Volunteers
- 201 people
- Sponsor
- Novartis Pharmaceuticals